Leaflet GEMCITABINA ACCORD 100mg / ml concentrate for solution for infusion


Indicated for: cancer

Route of administration: infusion

Substance: gemcitabine (antimetabolite antineoplastic)

ATC: L01BC05 (Antineoplastic and immunomodulating agents | Antimetabolites | Pyrimidine analogues)

Gemcitabine is a chemotherapy medication used to treat various types of cancer, including lung, pancreatic, breast, and bladder cancer. It is an antimetabolite that interferes with DNA synthesis in cancer cells.

This medication is administered intravenously, usually in cycles, according to a schedule set by the doctor. Gemcitabine helps slow the growth and spread of cancer cells.

Common side effects include nausea, vomiting, fatigue, low blood cell counts, and hair loss. In rare cases, severe reactions such as liver or lung function impairment may occur.

It is essential to follow your doctor's instructions and undergo regular tests to monitor the treatment's effects and manage potential side effects.

General data about GEMCITABINA ACCORD 100mg / ml

  • Substance: gemcitabine
  • Date of last drug list: 01-05-2026
  • Commercial code: W65796003
  • Concentration: 100mg / ml
  • Pharmaceutical form: concentrate for solution for infusion
  • Quantity: 1
  • Product type: generic
  • Price: 172.88 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE
  • Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
  • Number: 11693/2019/03
  • Shelf life: 2 years-after packing for marketing;dupa dilutie-se utilizeaza

Pharmaceutical forms available for gemcitabine

Concentrations available for gemcitabine

  • 1000mg
  • 100mg/ml
  • 10mg/ml
  • 1g
  • 2000mg
  • 200mg
  • 38mg/ml
  • 40mg/ml